| Issue Date | Title | Author(s) |
| Dec-2022 | Comparison of adjuvant gemcitabine plus S-1 with S-1 monotherapy for pancreatic ductal adenocarcinoma: Retrospective real-world data | Tang, Hui; Qiao, Caixia; Lu, Jun; Cheng, Yuejuan; Dai, Menghua; Zhang, Taiping; Guo, Junchao; Wang, Yingyi; Bai, Chunmei |
| 2019 | Serial Monitoring of Circulating Tumor DNA in Patients With Metastatic Colorectal Cancer to Predict the Therapeutic Response | Jia, Ning; Sun, Zhao; Gao, Xin; Cheng, Yuejuan; Zhou, Yanping; Shen, Chunying; Chen, Wei; Wang, Xueliang; Shi, Rong; Li, Nan; Zhou, Jianfeng; Bai, Chunmei |
| 2016 | Serum chromogranin A levels for the diagnosis and follow-up of well-differentiated non-functioning neuroendocrine tumors | Cheng, Yuejuan; Sun, Zhao; Bai, Chunmei; Yan, Xiaoyan; Qin, Ran; Meng, Changting; Ying, Hongyan |
| Nov-2020 | Surufatinib in advanced pancreatic neuroendocrine tumours (SANET-p): a randomised, double-blind, placebo-controlled, phase 3 study | Xu, Jianming; Shen, Lin; Bai, Chunmei; Wang, Wei; Li, Jie; Yu, Xianjun; Li, Zhiping; Li, Enxiao; Yuan, Xianglin; Chi, Yihebali; Yin, Yongmei; Lou, Wenhui; Xu, Nong; Bai, Yuxian; Zhang, Tao; Xiu, Dianrang; Wang, Xiuwen; Yuan, Ying; Chen, Jia; Qin, Shukui; Jia, Ru; Lu, Ming; Cheng, Yuejuan; Zhou, Zhiwei; Li, Jing; He, James; Su, Weiguo |
| 2019 | Surufatinib in Advanced Well-Differentiated Neuroendocrine Tumors: A Multicenter, Single-Arm, Open-Label, Phase Ib/II Trial | Xu, Jianming; Li, Jie; Bai, Chunmei; Xu, Nong; Zhou, Zhiwei; Li, Zhiping; Zhou, Caicun; Jia, Ru; Lu, Ming; Cheng, Yuejuan; Mao, Chenyu; Wang, Wei; Cheng, Ke; Su, Chunxia; Hua, Ye; Qi, Chuan; Li, Jing; Wang, Wei; Li, Ke; Sun, Qiaoling; Ren, Yongxin; Su, Weiguo |
